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                                           ABSTRACT     
BACKGROUND 
Stroke is one of the leading causes of morbidity and mortality in the 
general population. Apart from conventional risk factors, identifying potential 
modifiable risk factors can play a significant role in stroke prevention and 
outcome.  
AIMS AND OBJECTIVES 
This study aims to determine the frequency of subclinical hypothyroidism 
in patients presenting with acute ischemic stroke, its association with altered 
lipid metabolism and its role as an independent, modifiable risk factor in stroke 
prevention. 
MATERIALS AND METHODS 
85 patients presenting with acute ischemic stroke are taken as cases  and 
85 patients without stroke as controls matched for age,sex and risk factors. CT 
brain is done to confirm the diagnosis and thyroid profile measured. 
Patients with normal free T3, T4 and serum TSH above upper limit of 
normal are diagnosed to have subclinical hypothyroidism.  
The presence of subclinical hypothyroidism in both the cases and controls 
and its association with lipid abnormalities are analysed. 
 
OBSERVATION AND RESULTS 
Among the 85 patients with acute ischemic stroke, data analysis showed 
that 8.23% (7 out of 85) of them had subclinical hypothyroidism which was 
statistically significant with a p value of 0.007. Subjects in the control group 
had no subclinical hypothyroidism. Among the 7 cases with subclinical  
hypothyroidism, 6 (85.7 %) of  them had positive correlation with serum total 
cholesterol which was statistically significant. 
CONCLUSION 
The study results show a significant association of subclinical 
hypothyroidism with acute ischemic stroke and signifies its potential role as an 
independent, modifiable risk factor in stroke prevention.  
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INTRODUCTION 
Stroke or cerebrovascular accident is defined as an abrupt onset of a 
neurological deficit, either focal or global that is attributable to a vascular 
etiology. Definition of stroke is thus clinical and laboratory studies including 
brain imaging are used to support the diagnosis.  
The term cerebrovascular disease defines any brain lesion resulting from 
a pathologic process of the blood vessels such as occlusion of the lumen by 
embolus or thrombus, rupture of a vessel, an altered permeability of the vessel 
wall or a change in the quality of the blood flowing through the cerebral vessels. 
These are two main types—ischemia, with or without infarction and 
hemorrhage.  
There are two main types—ischemia, with or without infarction and 
hemorrhage. Stroke can also be classified in terms of the underlying 
pathogenesis involved, i.e., atherosclerosis, arteriosclerotic changes developing 
secondary to Hypertension, arteritis, aneurysmal dilatation and developmental 
vascular malformations of the brain. 
The clinical manifestations of stroke are highly variable because of the 
complex anatomy of brain and its vasculature. With the advent of imaging 
technologies, identifying a lesion as ischemia, infarct or hemorrhage has been 
made feasible to the attending physician. These methods help us to identify 
salvageable tissue during an acute phase of stroke. In advanced methods of 
stroke management, the objective is to identify ischemic, but not infarcted 
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tissue. Diffusion weighted imaging methods have been proved invaluable in 
stroke workup.  
In recent population based studies, the rate of incidence of stroke in India 
is found to be 119-145/100,000. The estimated adjusted prevalence rate of 
stroke ranges 84-262/100,000 in rural and 334-424/100,000 in urban areas.  
There are several risk factors for stroke which includes hypertension, 
diabetes mellitus, atrial fibrillation, cigarette smoking, and dyslipidemia. Other 
causes like hypercoagulable states and medications like birth control pills also 
contribute but only in special circumstances. In addition, hypothyroidism has 
been studied as an independent risk factor for causing ischemic stroke by 
accelerating the process of atherosclerosis.1 
Hypothyroidism is linked to altered lipid metabolism and lower levels of 
HDL cholesterol and higher levels of total cholesterol/HDL-C and LDL-
C/HDL-C ratios and also associated with elevated homocysteine levels. 
A number of clinical case reports, epidemiological studies, case -control 
and cohort studies have linked hypothyroidism and atherosclerosis2.  
 
  
 
 
 
 
 
AIMS AND 
OBJECTIVES 
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AIMS AND OBJECTIVES OF THE STUDY 
 
1. To determine the frequency of subclinical hypothyroidism in patients 
presenting with acute ischemic stroke. 
2. To study the association of subclinical hypothyroidism with altered lipid 
metabolism and its role in atherosclerosis. 
3. To study the role of subclinical hypothyroidism as an, independent, 
modifiable risk factor in stroke prevention. 
 
 
 
                                     
  
 
 
 
 
 
REVIEW OF 
LITERATURE 
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REVIEW OF LITERATURE 
 
Definition of Stroke 
The World Health Organization (WHO) definition of stroke is: “rapidly 
developing clinical signs of focal or global  disturbance of cerebral function, 
with symptoms lasting 24 hours or longer or leading to death, with no apparent 
cause other than of  vascular origin ”.  
 
Types of stroke 
Stroke can either be ischemic (with or without infarction) or hemorrhagic 
(intracerebral or subarachnoid). 
 
Ischemic stroke 
Ischemic stroke results from occlusion of the cerebral arteries by an 
atherosclerotic thrombus or from an emboli arising from the proximal part of 
the arterial system or the heart. Cardiac rhythm disturbances like atrial 
fribrillation  which results in stasis and blood clot formation, forms an important 
source of embolic stroke.  
This is to be differentiated from Transient Ischemic Attack (TIA) which 
resolves in less than 24 hours in spite of evidence of permanent brain injury on 
neuro imaging.  
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Figure 1 Atherosclerosis and acute ischemic stroke 
 
 Hemorrhagic stroke  
Besides trauma as an etiology, spontaneous intracerebral hemorrhages are 
mainly due to arteriolar hypertensive disease, and rarely due to coagulation 
disorders and vascular malformation within the brain. 
 Intra parenchymal hemorrhage due to hypertension and subarachnoid 
hemorrhage due to aneurysmal rupture are the two most common causes of 
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hemorrhagic stroke.Hemorrhagic stroke either by its mass effect on the 
surrounding structures or by raising the intracranial pressure produces 
significant neurological deficit.  
 
 
Figure 2 Types of Stroke 
 
In intracerebral hemorrhage, blood leaks from the vessel directly into the 
brain and hematoma occurs which causes mass effect on the surrounding brain 
and physical disruption of the nerve tissue.  As the leakage gets arrested, the 
blood slowly disintegrates and is absorbed over a period of weeks and months. 
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Subarachnoid hemorrhage results from rupture of aneurysms present at the 
branching points of the large arteries of the circle of Willis, the blood is contained 
within the subarachnoid spaces and therefore, causes little focal effect on the brain. 
However, when there is severe  bleeding it causes a delayed cerebral ischemia 
through a mechanism of constriction of the vessels of the circle of Willis and their 
primary branches (vasospasm).  
The Stroke Syndrome 
Stroke in its mildest form may consist of a trivial and transient neurologic 
disorder insufficient for the patient even to seek medical attention whilst in the 
most severe form the patient becomes hemiplegic or even comatose. 
However, the essential feature in all forms of stroke is the temporal profile 
of neurologic events irrespective of the grading of severity between these two 
extremes. The abruptness with which the neurologic deficit develops usually in a 
matter of seconds helps in making a diagnosis of vascular origin.  
Based on Time of onset  
Most embolic strokes characteristically have a sudden onset and the deficit 
reaches its peak almost at once. Thrombotic strokes also have an abrupt onset, but 
they evolve somewhat more slowly over a period of several minutes or hours and 
sometimes progresses in a saltatory fashion, i.e., in a series of steps. Hypertensive 
cerebral hemorrhage is sudden in onset but the deficit may be either static or 
steadily progressive over a period of minutes or hours whilst in subarachnoid 
hemorrhage it is almost instantaneous. 
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Based on pattern of involvement 
The second essential feature is the focal signature of stroke. The 
neurologic deficit helps in localizing the anatomical site inolved and also in 
estimating the size of the infarct or hemorrhage. Hemiplegia stands as the 
classic sign of all cerebrovascular diseases, whether the lesion is restricted to the 
cerebral hemisphere or when it also involves the brainstem with accompanying 
other diverse manifestations but in highly recognizable patterns. These include 
paralysis, numbness and sensory deficits on one side of the body, aphasia, 
visual field defects, diplopia, dizziness and dysarthria. The different patterns of 
involvement enable the physician to localize the lesion at times so precisely to 
even specify the culprit artery involved. 
  The territory of any artery, large or small, deep or superficial, may be 
involved. When an infarct involves the territory of a carotid artery, unilateral 
signs predominate: hemiplegia, hemianesthesia, hemianopia, aphasia, and 
agnosias are the common manifestations. In lesions involving the basilar artery 
territory, the signs of infarction are frequently bilateral and occur in association 
with cranial nerve palsies and other segmental brainstem and cerebellar signs; 
quadriparesis, hemiparesis, and unilateral or bilateral sensory impairment are 
present coupled with diplopia, dysarthria, ataxia, and vertigo in various 
combinations. 
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Based on sequence of resolution of neurological deficit 
Excluding fatal strokes another important aspect in the temporal profile of 
stroke evolution is the arrest and then partial regression of the neurologic deficit 
in almost all cases. A focal syndrome of rapid regression that reverses itself 
entirely and dramatically over a period of minutes or up to an hour has been 
defined as the "transient ischemic attack" (TIA). Often, an extensive deficit 
from embolism also partially reverses itself within a few hours or days. In most 
cases of thrombotic strokes, improvement occurs gradually over weeks and 
months, and there is considerable residual disability.  
So a gradual downhill course over a period of several days or weeks helps 
in making an alternative diagnosis of non vascular etiology. However there are 
exceptions, as in patients with multiple vascular occlusions and progression of a 
focal deficit due to brain edema developing secondary to large infarctions or 
hemorrhage. 
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Figure 3 CT Brain Showing Infarct 
 
Pathophysiology of Cerebral Ischemia 
The brain derives its nourishment from a constant and adequate supply of 
oxygenated blood and this is maintained by a series of baroreceptors and 
vasomotor reflexes under the control of centers in the lower brainstem. So any 
disturbance in this hemostasis for eg the complete stoppage of blood flow for 
longer than 5 min produces irreversible brain damage. At autopsy, this damaged 
brain tissue which undergoes ischemic necrosis or infarction is seen as a zone of 
softening or encephalomalacia. Focal ischemic damage usually results from 
occlusion of an artery by a thrombus or embolus, but cardiac failure resulting in 
Area of 
Infarction 
with 
surrounding 
edema 
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hypotension when severe and prolonged enough, can be the cause of focal as 
well as diffuse ischemic changes. 
 
Several additional ischemia-modifying factors may influence the extent 
of necrosis. The speed of occlusion has a significant effect- with gradual 
narrowing of a vessel allowing time for collateral channels to open. Hypoxia 
and hypercapnia have additional deleterious effects. Altered viscosity and 
osmolality of the blood and hyperglycemia are other important factors. Finally, 
vascular anomalies (of neck vessels, circle of Willis) and the presence of 
previous vascular occlusions also influence the outcome. 
 
Cerebral infarcts vary greatly depending on the amount of congestion and 
hemorrhage found within the softened tissue. Pale infarcts are devoid of blood; 
few infarcts show mild congestion (dilatation of blood vessels) at their margins 
while hemorrhagic infarcts show an extensive extravasation of blood from many 
small vessels in the infarcted area. 
 
 Many infarcts show a mixed pattern. Like  hemorrhagic infarction  which 
occurs in cases of cerebral embolism, results when an embolic material, after 
occluding an artery results in ischemic necrosis of brain tissue, fragments and 
then migrates distally from its original site. This allows partial restoration of the 
circulation to the infarcted zone, and blood seeps through the damaged small 
vessels to produce hemorrhage. Stroke from occlusion of veins in the cerebrum 
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also show a mixed type and has special characteristics of not conforming to the 
territories of the main cerebral arteries and usually contains substantial 
hemorrhage within the infarcted zone. 
 
 
 
Figure 4 Infarct with hemorrhagic transformation 
 
 
  
Acute 
Infarct 
Hemorrhag
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RISK FACTORS FOR CEREBROVASCULAR DISEASE  
Important risk factors for stroke have been identified as age, sex, blood 
pressure, hyperglycemia, dyslipidemia, smoking, alcoholism, sedentary lifestyle 
and dietary habits. Besides the above mentioned factors, ischemic and valvular 
heart disease, atrial fibrillation and history of similar events in the past also 
increase the risk of stroke. 
Patient’s socioeconomic condition, ethnicity, educational status and 
environmental factors like physical (temperature, altitude), geographical, or 
psychosocial issues also seem to play a role.4  
 Exposure to environmental tobacco smoking have been studied as an 
independent risk factor for stroke. As in coronary artery disease, the level of 
low-density lipoprotein (LDL) cholesterol has the greatest impact on the 
incidence of stroke with elevated triglycerides also conferring additional risk. 
Other factors, such as low potassium intake and reduced serum potassium are 
also associated with an increased stroke rate in several studies, but the 
mechanism of this effect is obscure with a detrimental effect on blood pressure 
being a likely possibility.  
 
HYPERTENSION AND STROKE 
The longitudinal analytical study done on Framingham’s5  adult 
population clearly defines hypertension as a major risk factor for stroke. It is 
associated with an increased incidence of both haemorrhagic, ischaemic and 
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lacunar stroke.  A transient rise in blood pressure is common in acute stroke and 
in cases with pre-existing chronic hypertension. Based on major controlled 
trials, no evidence exists for acutely lowering blood pressure in such patients 
and suggests allowing blood pressures in acute stroke to settle spontaneously 
unless very high. 
 
PATHOPHYSIOLOGY 
  High blood pressure results in endothelial injury which increases blood-
brain barrier permeability leading to brain oedema6 and mass effects due to 
raised intra cranial pressure. Intraparenchymal  haemorrhages results from 
smooth muscle cell and endothelial degeneration.  
 
1. In addition, it increases cerebral artery stenosis and increased incidence 
of embolism arising from the heart and great vessels by accelerating the 
process of arteriosclerosis.  
 
2. The structural derangements in the resistance vessels leads to increase in 
peripheral vascular resistance thereby increasing the risk for ischaemic 
events by compromising on the collateral blood supply. 
 
3. The high blood pressure produces endothelial injury, attracts leucocytes 
to the site of injury and converts LDL to its oxidized form with smooth 
muscle proliferation resulting in formation of foam cells, which plays a 
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central role in atherogenesis and plaque formation and occlusion of the 
vessel lumen resulting in reduced blood supply distal to the site of 
occlusion. 
 
 
Figure 5 Pathogenesis of Atherosclerosis 
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 Figure 6  Vascular Changes in Hypertension 
 
INDICATIONS FOR ANTI-HYPERTENSIVE THERAPY IN ACUTE 
STROKE 
For patients with stroke who are not candidates for thrombolytic therapy, 
the recommended guideline7 to initiate anti-hypertensive therapy is when blood 
pressure is  above 220/130 mm Hg and if thrombolytic therapy8 is to be used, 
the goal blood pressure is <185/110 mm Hg. 
For patients presenting with hemorrhagic stroke, therapy can be initiated 
at blood pressures above 180/130 mm Hg.  
In subarachnoid hemorrhage, cautious reduction of blood pressure is 
indicated when mean arterial pressure is >130 mm Hg. 
 Hyaline 
arterioscler
osis  and 
Fibrinoid 
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DIABETES AND STROKE 
 Diabetes has been proven to be a significant independent risk factor9 for 
stroke; the risk in diabetics being 2 to 4 fold greater than in normal population. 
It is also an important risk factor for morbidity and mortality associated with 
stroke, with increased incidence of severe neurological deficits and disability10, 
higher incidence of stroke recurrence11-12 and a poorer long-term prognosis. 
 
Diabetes is associated with both microvascular and macrovascular 
complications affecting several organs including heart,brain, kidneys, skin and 
muscle. Impaired glucose metabolism in diabetics may favour the initiation of 
vascular complications through structural derangements mediated by advanced 
glycation end products and production of  reactive oxygen species.  
 
The role of diabetes in stroke has been attributed to the 
pathophysiological changes seen in the cerebral vessels of patients which 
includes 
 1. The pathologic effects of advanced glycation end product 
accumulation 
2.  Nitric oxide inhibition leading to impaired vasodilation,  
3.  Chronic inflammation  
4.  Smooth muscle cell proliferation, 
5.  Overproduction of endothelial growth factors, 
6.  Impaired fibrinolytic activity and  
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7.  Enhanced platelet aggregation 
 
Apart from diabetes being an independent risk factor for stroke, it also 
increases the incidence of other conventional risk factors which includes 
hypertension, heart failure, dyslipidemia, and atrial fibrillation.13 
PATHOGENESIS 
Endothelial injury marks the initiation of macrovascular complications in 
diabetes, with other factors super imposed on it. 
 
Chronic hyperglycemia by inhibiting nitric oxide reduces the vasodilatory 
response14 through inhibition of endothelial nitric oxide synthase (eNOS) and 
increases the production of reactive oxygen species,that  leads to further 
inhibition of eNOS.15-16.  
 
In addition, insulin resistance leads to an increase in free fatty acid 
release from the adipose tissue which in turn stimulates the PKC pathway. And 
this results in increased ROS generation that further leads to inhibition of eNOS 
activity. The production of advanced glycosylation end products also inhibits 
NO production18 all contributing to impaired vasodilation. Apart from the 
impaired vasodilatory response, an overproduction of vasoconstrictor 
substances like endothelin-1 occurs, which has direct vasoconstrictive  
endothelial effects and indirect fluid volume effects resulting in  water and salt 
retention and the activation of the RAS. 
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Figure 7 Mechanism of Endothelial dysfunction in diabetes 
Impaired platelet function leading to rupture of atherosclerotic plaque17 
and thrombus formation may underlie the pathogenesis of macrovascular 
complications in diabetes. 
 
Chronic inflammatory state also plays a central role in the development 
of atherosclerosis related diabetic macrovascular pathology. Endothelial injury 
results in recruitment of inflammatory cells like monocytes and T lymphocytes 
which adhere to the injured surface and travel to the intima media of arteries, 
wherein they engulf oxidized LDL forming foam cells18 that plays the key role 
in formation of atherosclerotic plaques.  
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  Smooth muscle cell dysfunction contributes to the structural vessel wall 
abnormalities seen in diabetes. Following endothelial injury, smooth muscle 
cells in the tunica media migrate to the intimal layer producing solidification of 
the atherosclerotic fatty streaks and resulting in an extensive extracellular 
matrix, thereby weakening the tunica media and resulting in plaque rupture.  
 
A unique effect of diabetes on cerebral vasculature is its effect on neurons 
and glial cells which occurs during ischemia. This has been explained through 
the relationship between hyperglycemia and increased intracellular acidosis.145 
Anaeroic metabolism that occurs during an ischemic event, for instance 
as in stroke produces neuronal intracellular acidosis which causes nerve cell 
damage through the mechanism of Reactive Oxygen Species (ROS) 
production.19 
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Figure 8 Role of inflammation in atherosclerosis 
 
STROKE AND DYSLIPIDEMIA 
  Thromboembolism is considered the most common pathology leading to 
ischaemic stroke, this thromboembolism occurs as a result of atherosclerosis. 
Nikolai in 1912  was the first to propose the association between cholesterol, 
and stroke . In what is considered as a breakthrough study in 20th century 
Nilkolai and his team proved that the obstructive pathology occurring in 
atheroscelrosis was due to an elevated level of serum cholesterol. 
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According to recent studies ,apart from  elevated  LDL other lipids like 
the reduced levels of HDL-c, increased triglycerides and Apolipoprotein B are 
also found contributing to the stroke risk. Atherogenic dyslipidemia  comprising 
of reduced HDL-c and an elevated TGL  has been proved to be an independent 
risk factor of increased vascular risk. The MRFIT study conducted on 3,50,977 
individuals has proved a positive correlation between total cholesterol levels 
and risk of ischaemic stroke.5    Furthermore , its proved that the relative risk for 
stroke doubles every decade after the age of 55.8,9 
 High density lipoprotein (HDL–c) in reduced concentration ,an 
independent risk factor of atherosclerosis is also considered a risk for stroke. 
Numerous  prospective studies have proved a significant reduction in non fatal 
stroke in subjects with an elevated or normal HDL-c levels10. The levels of 
HDL-c were inversely correlated with atheroma burden. The plasma levels of 
triglyceride has no independent predictive value in stroke risk. 
                Lipoproteins- no concrete evidence exists pointing to the connection 
between stroke risk and lipoprotein levels. There are  controversial studies 
denoting the association between lipoprotein–a and stroke incidence20.the 
association between the levels of Apo E and the cerebrovascular risk is also 
under study. Few other studies indicate the positive predictive capacity of Apo 
B , and Apo A1 in cerebrovascular events. 
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 Further, treatment of dyslipidemia is associated with significant risk 
reduction in stroke. According to the CARE25  ,PROSPER ,ASCOT trials there 
is a proven in reduction in stroke risk by 31 %, on treatment with statins aimed 
at reducing LDL levels. 
STROKE AND HEART DISEASES 
Cardioembolic stroke results when a thrombus within the heart chambers 
breaks and dislodges embolic fragments into the vessel wall. Sometimes an 
emboli may originate from the distal end of a thrombus intraarterially, in a 
severely stenosed or occluded carotid or vertebral artery or from large 
atheromatous plaques in the aorta. 
 Arrhythmias such as atrial fibrillation, secondary to valvular heart 
diseases or ischemic heart disease and atrial myxoma also predispose to embolic 
stroke. Thrombotic or infected material e.g. as in infective endocarditis which  
adheres to the aortic or mitral heart valves and  clots originating on prosthetic 
heart valves also break free to produce embolic stroke. 
 
  Ischemic infarction results when the embolus becomes arrested at a 
bifurcation or at the site of natural narrowing of the lumen of an artery. The 
infarction may be pale, hemorrhagic or mixed; hemorrhagic infarction mostly 
always indicates embolism as does venous occlusion. Any region of the brain 
may be affected with the territories of the middle cerebral artery, especially the 
superior division, being the most frequently involved. Large embolic clots can 
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block large vessels like the carotids in the neck, while tiny fragments may reach 
vessels as small as 0.2 mm in diameter, usually with minimal effects. 
 
As embolic strokes develops rapidly, collateral blood supply does not 
become established and hence sparing of the brain territory distal to the site of 
occlusion as seen in slowly developing thrombotic strokes  is usually not  
evident. 
The most common cause of an embolic stroke being a chronic or recent 
atrial fibrillation, it usually arises from a mural thrombus within the atrial 
appendage. 
 
Figure 9  Embolic Stroke in Atrial  Fibrillation 
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Based on the Framingham Heart Study, patients with chronic atrial 
fibrillation are approximately 6 times more prone to stroke than an age-matched 
population with normal cardiac rhythm (Wolf et al, 1983) and the risk is higher 
if rheumatic valvular heart disease is also present. 
Furthermore, the risk for stroke in patients with atrial fibrillation varies 
with age, being 1 percent per year in persons younger than age 65 years, and as 
high as 8 percent per year in those older than age 75 years with additional risk 
factors. These play a significant role in determining the benefit of chronic 
anticoagulation therapy.  
 
Embolism also occurs in cases of paroxysmal atrial fibrillation or flutter. 
Post myocardial infarction, mural thrombus formed on the damaged 
endocardium in the left ventricle, particularly if there is an aneurysmal sac, is an 
important source of cerebral emboli. 
 
  Emboli mostly tend to occur in the first few weeks after an acute 
myocardial infarction but Loh and colleagues found that a lesser degree of risk 
persists even upto 5 years. Cardiac catheterization or surgery, especially 
valvuloplasty, may disseminate fragments from a thrombus or a calcified valve. 
Mitral and aortic valve prostheses are also additional important sources of 
embolism. 
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STROKE AND TOBACCO USE 
           Smoking as an independent risk factor has been known to double the risk 
of ischemic stroke.  Cigarette smoke is generally divided into two phases which 
include a tar phase (particulate phase) and a gas phase. When passed through 
the Cambridge glass-fiber filter, the material that gets trapped is the tar phase 
with a particulate material of size >0.1µm. While the material that passes 
through the filter comprises the gas phase.     
 
 The particulate phase of cigarette smoke contains more than 1017 free 
radicals/g, and  gas phase contains more than 1015 free radicals/puff .The 
radicals related to the particulate phase have a longer life span ( hours to 
months) where as those associated with gas phase are short lived(seconds). It is 
found that amidst all the identified constituents, nicotine found in the particulate 
phase, is the addictive substance in cigarette smoke. 
 
             Active smoking as well as passive smoking has been found to be related 
to a constant increase in carotid artery intimal-medial thickness. By modifying 
the activity of the endothelial NO synthetase enzyme and inhibiting nitric oxide 
production cigarette smoking impairs the vasodilation  in macrovascular as well 
as in microvascular beds. Apart from serving a vasoregulatory function21 NO 
also it plays a vital role in  regulating  inflammation by preventing leukocyte 
adhesion as well as platelet activation. Hence, an alteration in NO production 
hastens the process of atherosclerotic events. 
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Figure 10 Role of Nitric Oxide in  Endothelial vasodilation 
 
SMOKING AND INFLAMMATION 
      The inflammatory response plays a central role in the instigation and 
progression of atherosclerosis. Based on various studies, evidence exists about 
smoking causing a significant increase in the peripheral leukocyte count. 
Inflammatory markers like C-reactive protein, interleukin-6, and tumor necrosis 
factor- alpha(TNF-α)  have also been found to be significantly increased  in 
smokers 22. 
  
 Elevation of several proinflammatory cytokines increases leucocyte 
endothelial cell interaction leading to atherogenesis and recruitment of 
leucocytes which is the early event in the pathogenesis of atherosclerosis.  It 
was found that the soluble adhesion molecules such as  ICAM-1, VCAM-1 and 
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E-Selectin levels were  higher in smokers than non smokers. It also activates 
proatherogenic molecules resulting in  alteration in cell-cell interactions and 
helps in hastening the process of atherosclerosis. 
 
 Smokers have higher serum total cholesterol, LDL and triglyceride levels 
and lower levels of HDL. The triglyceride and high-density lipoprotein 
abnormalities have been found to be linked to insulin resistance.  
It increases oxidation of LDL molecules by decreasing the activity of 
paraoxonase, an enzyme that inhibits LDL oxidation.  
TREATMENT: ACUTE ISCHEMIC STROKE 
After the clinical diagnosis of stroke is made, an orderly process of 
evaluation and treatment should follow. The first goal is to prevent or reverse 
brain injury. Attend to the patient's airway, breathing, circulation (ABC's). 
Perform an head CT scan to differentiate between ischemic stroke and 
hemorrhagic stroke. 
Medical Support 
When ischemic stroke occurs, the immediate goal is to optimize cerebral 
perfusion in the surrounding ischemic penumbra. Attention is also directed 
toward preventing infections (pneumonia, urinary, and skin) and deep venous 
thrombosis (DVT) with pulmonary embolism.  
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Because collateral blood flow within the ischemic brain is blood pressure 
dependent, there is controversy about whether blood pressure should be lowered 
acutely. Blood pressure should be lowered if there is malignanthypertension or 
if blood pressure is >185/110 mm Hg and thrombolytic therapy is anticipated. 
Fever is detrimental and should be treated with antipyretics and surface cooling. 
Serum glucose should be monitored and kept at <6.1 mmol/L (110 mg/dL) 
using an insulin infusion if necessary. 
The larger the infarct, the greater the likelihood that clinically significant 
edema will develop. Water restriction and IV mannitol may be used to raise the 
serum osmolarity, but hypovolemia should be avoided as this may contribute to 
hypotension and worsening infarction.  
Intravenous Thrombolysis 
The NINDS study used IV rtPA (0.9 mg/kg to a 90-mg max, 10% as a 
bolus, then the remainder over 60 minutes) versus placebo in patients with 
ischemic stroke within 3 hours of onset. One-half of the patients were treated 
within 90 minutes. Thus, despite an increased incidence of symptomatic 
intracerebral hemorrhage, treatment with IV rtPA within 3 hours of the onset of 
ischemic stroke improved clinical outcome. 
Use of IV tPA is now considered a central component of primary stroke 
centers as the first treatment proven to improve clinical outcomes in ischemic 
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stroke and is cost-effective and cost-saving. The time of stroke onset is defined 
as the time the patient's symptoms began or the time the patient was last seen as 
normal. Patients who awaken with stroke have the onset defined as when they 
went to bed. 
Antithrombotic Treatment 
Platelet Inhibition 
Aspirin is the only antiplatelet agent that has been proven effective for the 
acute treatment of ischemic stroke; there are several antiplatelet agents proven 
for the secondary prevention of stroke. Use of aspirin within 48 hours of stroke 
onset reduced both stroke recurrence risk and mortality minimally. The 
glycoprotein IIb/IIIa receptor inhibitor abciximab was found to cause excess 
intracranial hemorrhage and should be avoided in acute stroke. Clopidogrel is 
being tested as a way to prevent stroke following TIA and minor ischemic 
stroke. 
Lipid Lowering drugs 
Statins are used after an episode of cerebro vascular accident by reducing 
the lipid levels helps in delaying the further progression of atherosclerosis and 
stabilizes the plaque preventing its rupture and thrombus formation.  
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HYPOTHYROIDISM 
 
THYROID: ANATOMY AND DEVELOPMENT 
               The thyroid gland derives its origin from the greek word ‘thyreos’ 
denoting shield and it comprises of two lobes joined by an isthmus. It lies in 
front of the trachea extending from  the cricoid cartilage to the suprasternal 
notch. The gland is  highly vascular, soft in consistency and weighs around 12–
20 g. The thyroid gland develops from the floor of the  pharynx and  migrates 
along the thyroglossal duct to reach its final location in the neck. Thyroid 
hormone synthesis  begins as early as around 11 weeks gestation. The hormones 
secreted by the thyroid gland play a key role in cell differentiation during 
development and helps to maintain thermogenic and metabolic homeostasis in 
the adult 
             Thyroid gland development is due to the coordinated expression of 
several developmental transcription factors like thyroid transcription factor 
(TTF)-1, TTF-2, and paired homeobox-8 (PAX-8) which  are expressed 
selectively in the thyroid gland. These factors are also responsible for induction 
of thyroid-specific genes such as thyroglobulin (Tg), thyroid peroxidase (TPO), 
the sodium iodide symporter (Na+/I, NIS), and the thyroid-stimulating hormone 
receptor (TSH-R). Occurrence of  mutation in these  transcription factors or 
their target genes are rare causes of thyroid agenesis or dyshormonogenesis, 
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though in most cases,etiology of congenital hypothyroidism remains unknown.  
           The thyroid gland consists of numerous spherical follicles that contain 
colloid rich in  thyroglobulin, which is essential for thyroid hormones synthesis. 
 
Figure 11 Thyroid Gland 
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REGULATION OF THYROID AXIS 
         Thyroid stimulating hormone( TSH), secreted by the thyrotrope cells of 
the anterior pituitary  is a 31-kDa hormone composed of α and β subunits; the α 
subunit which shares similarity to many other glycoprotein hormones 
[luteinizing hormone, follicle-stimulating hormone, human chorionic 
gαonadotropin ], whereas the β subunit is unique to TSH.  
            The thyrotropin releasing hormone (TRH) from the hypothalamus 
stimulates the pituitary production of TSH which stimulates thyroid gland to 
produce the thyroid hormones T3 and T4. Thyroid hormones, acting 
predominantly through thyroid hormone receptor β 2, sends feed back to 
pituitary and hypothalamus to inhibit TSH and TRH respectively.  
           Like other pituitary hormones, TSH is the main regulator of this 
endocrine feedback loop mechanism. TSH is measured using 
immunoradiometric assays which are highly sensitive and specific. And  TSH 
can be used for the diagnosis of hyperthyroidism (low TSH) as well as 
hypothyroidism (high TSH). Drugs like dopamine, glucocorticoids and 
somatostatin when administered exogenously suppress TSH function. 
                 Reduced levels of T3 and T4 enhance TSH production whereas higher 
levels suppress TSH levels, thereby underscoring the importance of these 
hormones in the regulation of TSH production.  
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Figure 12 Hypothalamo-pituitary-thyroid axis. 
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THYROID HORMONE SYNTHESIS AND FUNCTION 
Iodine Metabolism and Transport 
The first critical step in thyroid hormone synthesis is Iodine uptake23. 
Iodine from diet is carried by serum binding proteins, particularly albumin from 
where it is taken into thyroid follicular cells by NIS( sodium iodide symporter) 
expressed at its basolateral membrane.  
Adaptations to variations in dietary intake of iodine is highly regulated by 
this symporter function and expression.  One of the rare causes of congenital 
hypothyroidism  is mutation of the NIS gene. 
  Based on urinary excretion data, iodine deficiency is more prevalent in 
many mountainous regions, central Africa, central South America and northern 
Asia and it remains the most common cause of preventable mental deficiency 
.There is an increased prevalence of goiter in areas of relative iodine deficiency 
and when it becomes more pronounced results in cretinism in 
children,characterised by mental and growth retardation and wide range of 
cognitive dysfunction and metabolic disturbances in adults. 
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Organification, Coupling, Storage, Release                            
Following uptake into follicular cells, iodine is oxidized in an 
organification reaction catalysed by TPO and hydrogen peroxide and is added to 
selected tyrosyl residues within Tg   to form diiodotyrosine(DIT) and 
monotyrosine(MIT).These are further coupled via an ether linkage involving  
thyroperoxidase(TPO) with coupling of two molecules of DIT or one of DIT 
and one of MIT leading to formation of T4 and T3, respectively. Reuptake of Tg 
into the thyroid follicular cell allows proteolysis and the release of newly 
synthesized T4 and T3.   
                  Uncoupled mono- and diiodotyrosines (MIT, DIT) are deiodinated 
by the enzyme dehalogenase, thereby recycling any iodide that is not converted 
into thyroid hormones. 
      In most cases of congenital hypothyroidism,the etiology remains 
unknown while rare causes have been attributed to recessive mutations in TPO 
or Tg mainly, but defects have also been identified in the TSH-R, NIS, pendrin, 
hydrogen peroxide generation, and dehalogenase. 
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Figure 13 Thyroid Hormone Synthesis 
TSH Action 
TSH regulates thyroid gland function through the TSH-R, a seven-
transmembrane G protein–coupled receptor (GPCR) that is coupled to the 
subunit of stimulatory G protein (Gs), which activates adenylyl cyclase, leading 
to increased production of cyclic AMP. Recessive loss-of-function mutations 
causes thyroid hypoplasia and congenital hypothyroidism and dominant gain-of-
function mutations cause sporadic or familial hyperthyroidism that is 
characterized by goiter, thyroid cell hyperplasia, and autonomous function 
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Other Factors that Influence Hormone Synthesis and Release 
Apart from TSH being the prime hormonal regulator of thyroid function, 
a variety of growth factors also influence thyroid hormone synthesis. These 
include insulin-like growth factor I (IGF-1), epidermal growth factor, 
transforming growth factor (TGF-), endothelins, and various cytokines. In 
individuals with a normal thyroid, the gland escapes from inhibitory effect of 
excess iodide, however the suppressive action of high iodide may persist in 
patients with underlying autoimmune thyroid disease. 
Serum Binding Proteins 
T4 is secreted in about twentyfold excess over T3 and.both hormones are 
bound to plasma proteins, including thyroxine-binding globulin (TBG), 
transthyretin (TTR, formerly known as thyroxine-binding prealbumin, or 
TBPA), and albumin. These proteins by increasing the circulating pool and 
delaying clearance modulate hormone delivery to selected tissue sites.  
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Characteristics of Circulating T4 and T3 
 
 
Hormone Property T4 
 
T3 
Serum concentrations   
Total hormone 8 g/dL 0.14 g/dL 
Fraction of total hormone in the free form 0.02% 0.3% 
Free (unbound) hormone 21 × 10–12M 
 
6 × 10–12M 
 
Serum half-life 7 d 0.75 d 
Fraction directly from the thyroid 100% 20% 
Production rate, including peripheral conversion 90 g/d 32 g/d 
Intracellular hormone fraction 20% 70% 
Relative metabolic potency 0.3 1 
Receptor binding 10–10M 
 
10–11M 
 
 
Table 1: Characteristics of Circulating T4 and T3s 
Despite its low serum concentration,TBG carries about 80% of the bound 
hormones due to  its high affinity for thyroid hormones. Whereas albumin with 
a high plasma concentration has relatively low affinity for thyroid hormones 
and it binds up to 10% of T4 and 30% of T3. TTR carries about 10% of T4 but 
little T3. 
Approximately 99.98% of T4 and 99.7% of T3 are protein-bound and 
since T4 is more avidly bound to plasma proteins than  T3, the proportion of 
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unbound T3 > unbound T4, but there is less unbound T3 in the circulation as it is 
produced in smaller amounts and cleared more rapidly than T4 
Nuclear Thyroid Hormone Receptors 
Thyroid hormones24 bind with high affinity to nuclear thyroid hormone 
receptors (TRs) α and β..The receptors bind as heterodimers with retinoic acid 
X receptors (RXRs) and then to specific DNA sequences, termed thyroid 
response elements (TREs), in the promoter regions of target genes. The 
activated receptor then in turn can stimulate gene or inhibit transcription 
depending on the nature of the regulatory elements in the target gene. 
Though T4 is produced in excess of T3, receptors are occupied mainly by 
T3 owing to their high affinity and greater plasma availability resulting in 
maximum hormonal potency. After binding to TRs, thyroid hormone induces 
conformational changes in the receptors leading to alteration in gene expression. 
Laboratory Evaluation 
Measurement of Thyroid Hormones 
The immunochemiluminometric assays (ICMAs) for TSH  are specific 
and sensitive enough to detect very low levels of TSH (0.1 mU/L).  The first 
step in evaluating thyroid dysfunction is to measure TSH levels as suppressed, 
normal or high in response to alterations in levels of T3 and T4. This is followed 
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by measurements of serum T3 and T4 levels to make a diagnosis of hypo (with 
elevated TSH) or hyperthyroidism (with suppressed TSH levels).   
As total T4 and T3 are highly protein-bound and influenced by numerous 
factors like illness, medications and genetic factors it is useful, therefore, to 
measure the free, or unbound, hormone levels, which reflects the biologically 
active hormone pool. 
Total T4 and T3 levels are elevated when TBG is increased due to 
estrogens (pregnancy, oral contraceptives, hormone therapy, tamoxifen), and 
decreased when TBG binding is reduced (androgens, nephrotic syndrome). As 
total T4 and T3 are highly protein-bound and influenced by numerous factors 
like acute illness, genetic disorders  and various medications (phenytoin, 
carbamazepine, salicylates, and NSAIDs)which can interfere with thyroid 
hormone binding, it is preferable to measure the free, or unbound, hormone 
levels, which remains normal under such situations. 
In certain cases,TSH as a screening test without simultaneous unbound 
T4 determinations may be misleading. Although hypothyroidism is the most 
common cause of an elevated TSH level, rare causes include a TSH-secreting 
pituitary tumor, thyroid hormone resistance, and assay artifact. Conversely, a 
suppressed TSH level usually indicates thyrotoxicosis but may also be seen 
during the first trimester of pregnancy ,after treatment of hyperthyroidism  and 
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on exposure to certain drugs like dopamine or high doses of steroids.  
The most common antibodies detected in patients with auto immune 
thyroid disease is antibodies against TPO and Tg.  
Hypothyroidism 
 Iodine deficiency remains the most common cause of hypothyroidism 
worldwide. In areas of iodine sufficiency, autoimmune disease and iatrogenic 
causes are the most common causes. 
Symptoms 
    Tiredness, weakness 
    Dry skin 
    Feeling cold 
    Hair loss 
    Difficulty concentrating and poor 
memory 
    Constipation 
    Weight gain with poor appetite 
    Dyspnea 
    Hoarse voice 
    Menstrual disturbances 
     
Signs 
     Puffy face, hands, and feet 
(myxedema) 
    Diffuse alopecia 
    Dry coarse skin 
    Decreased heart rate 
    Carpal tunnel syndrome 
    Delayed tendon reflex relaxation 
    Serous cavity effusions 
 
 
Table 2: Signs and Symptoms of Hypothyroidism  
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Autoimmune Hypothyroidism 
Classification 
Autoimmunity is the most common cause of hypothyroidism which may 
be either associated with a goiter (Hashimoto's thyroiditis) or resulting in 
atrophy of the thyroid gland. As auto immunity progresses and reduces thyroid 
function, there is a compensatory rise in TSH levels to maintain normal thyroid 
hormone levels. With most of the patients being asymptomatic, this is termed 
subclinical hypothyroidism. It progresses to overt hypothyroidism when patients 
become symptomatic with reduced T4 levels, and a compensatory rise in TSH 
levels >10 mIU/L. 
Prevalence 
The mean annual incidence rate of autoimmune hypothyroidism is up to 4 
per 1000 women and 1 per 1000 men. It is found to be more prevalent in 
Japanese populations due to genetic factors and intake of high iodine diet. 
Subclinical hypothyroidism is found in 6–8% of women and 3% of men. When 
subclinical hypothyroidism is associated with positive TPO antibodies, the 
annual risk of developing clinical hypothyroidism rises to 4%. 
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Pathogenesis 
In Autoimmune thyroiditis25, there is lymphocytic infiltration of the 
gland, by CD4+ and CD8+ T cells resulting in atrophy and fibrosis of thyroid 
gland. CD8+ cytotoxic T cells mediate destruction by either perforin-induced 
cell necrosis or granzyme B–induced apoptosis.  
Genetic and environmental factors contribute to the development of 
autoimmune thyroid disorders, of which HLA-DR polymorphisms are the most 
widely recognized.  
By its direct toxic effects or through immune mediated mechanisms, high 
iodine intake  increases the risk of autoimmune hypothyroidism. 
Antibodies to TPO and Tg serve as the most clinical useful markers of 
thyroid autoimmunity. Up to 20% of patients with autoimmune hypothyroidism 
have antibodies against the TSH-R which prevent the binding of TSH, resulting 
in  hypothyroidism and especially in Asian patients, thyroid atrophy. This is in 
contrast to TSI, which does not stimulate the receptor and results in 
hypothyroidism. 
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Clinical Manifestations 
The skin is dry, coarse with decreased sweating, thinning of the epidermis 
and hyperkeratosis of the stratum corneum. Increased dermal 
glycosaminoglycan content traps water, giving rise to skin thickening without 
pitting (myxedema). A puffy face with edematous eyelids and nonpitting 
pretibial edema gives a typical picture of hypothyroid patients. The hair 
becomes dry, brittle and falls out easily resulting in diffuse alopecia, with 
thinning of the outer third of the eyebrows, though not specific for 
hypothyroidism. Nail growth retardation is also a common finding. 
Other common features include constipation and increase in weight 
which is due to fluid accumulation in the subcutaneous tissues. Decreased 
libido, reduced fertility and increased incidence of miscarriage is common 
which may be due to increased Prolactin levels. There may be oligomenorrhea 
or amenorrhea in long-standing disease, but menorrhagia is also common. 
Cardiovascular changes includes decreased myocardial contractility and 
pulse rate, leading to a reduced stroke volume and bradycardia and pericardial 
effusions (around 30%) which do not compromise cardiac function are also 
common. Increased peripheral resistance may contribute to the development of 
diastolic hypertension. Fluid may also accumulate in other serous cavities and in 
the middle ear, giving rise to conductive deafness. Though pulmonary function 
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remains normal, dyspnea may be caused by pleural effusion, impaired 
respiratory muscle function, diminished ventilatory drive, or sleep apnea. 
On examination, there may be slow relaxation of tendon reflexes and 
pseudomyotonia. Cognitive disturbances include memory  disturbances and 
poor concentration. 
DEFINITION OF SUBCLINICAL AND OVERT HYPOTHYROIDISM 
Overt hypothyroidism is diagnosed in patients who have symptoms of 
hypothyroidism, reduced levels of thyroid hormones T3, T4 and elevated TSH (> 
10µIU/ml) whereas a diagnosis of subclinical hypothyroidism is made when T3,  
T4 levels are within the normal range with mild elevations of TSH levels 
(<10µIU/ml) which act to maintain normal thyroid hormones but can eventually 
progress to overt hypothyroidism, when the compensatory mechanism is 
overwhelmed by the auto immune process. 
HYPOTHYROIDISM AND ENDOTHELIAL DYSFUNCTION 
The vascular homeostasis is maintained by the endothelium by a balance 
in the production of vasoconstrictor and vasodilator substances26. Nitric oxide, 
the most important vasodilator substance is produced by the endothelium during 
conversion of L-arginine into citrulline catalysed by the enzyme nitric oxide 
synthase. 
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In presence of increased serum cholesterol levels, due to increased 
oxidative stress the endothelium causes breakdown of nitric oxide production.In 
addition, endothelial dysfunction is also influenced to a major extent by other 
risk factors like aging, hypertension, smoking and post menopausal status.So 
dyslipidemia acts as an independent risk factor for altering endothelial function 
and in patients with subclinical hypothyroidism (SH) having abnormal lipid 
profile, this could play a role in mediating endothelial dysfunction. 
 
Evidence from a study conducted on patients with SH studied the 
vasodilating effect in response to acetylcholine and it was found to be 
significantly reduced in patients with SH compared to euthyroid controls. And it 
was also found to be impaired in patients with SH whose total serum cholesterol 
levels were in the normal range.This clearly indicates the direct effect of thyroid 
hormones as an independent risk factor in producing endothelial dysfunction in 
SH patients apart from the contributory effects of lipid abnormalities on 
endothelial function and NO production. 
 
In addition to this, the effect of autoimmunity and inflammation seen in 
hypothyroid patients may play a role. Most patients with subclinical 
hypothyroidism had evidence of autoimmune thyroiditis as documented by TPO 
autoantibodies. In the above study conducted to determine the effects of SH on 
endothelial function, Erythrocyte Sedimentation Rate (ESR) was measured and 
was found to be significantly raised and this contributes to the confirmation of 
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hypothesis that inflammation present in autoimmune thyroid disorders could 
also play a part in mediating impaired endothelial vasodilation. 
 
 But more specific inflammatory markers like C-Reactive Protein and 
interleukins need to be studied to confirm this hypothesis as ESR is a non 
specific inflammatory marker found to be raised in various other pathologies. 
 
 In patients with SH, lipoprotein a values were also found to be elevated 
and has a  significant co-relation with endothelial dysfunction in coronary 
circulation thereby contributing to coronary artery disease. 
 
 So all these factors in patients with subclinical hypothyroidism including 
thyroid dysfunction, chronic inflammatory state seen in autoimmune thyroid 
disorders and altered lipid metabolism leading to hypercholesterolemia could 
jointly contribute to the impaired endothelium dependent vasodilation seen in 
these patients. 
  This is also supported by the fact that treatment of SH with L-Thyroxine 
was found to restore an euthyroid state and an improvement in acetylcholine 
induced vasodilation and NO availability. On receiving replacement therapy, 
TSH levels were reduced, there was a decrease in serum total and LDL 
cholesterol levels and no significant changes in lipoprotein a levels.  
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So to conclude, subclinical hypothyroidism represents an early, 
independent,  reversible risk factor in causing endothelial dysfunction in 
addition to the co-existing lipid abnormalities seen in SH patients. This 
highlights the importance of early replacement therapy in not only delaying the 
progression to overt hypothyroidism but also in restoring endothelium 
dependent vasodilation, reversal of lipid abnormalities and slowing down the 
atherogenic process and its associated complications.  
 
 
Figure 14 Thyroid hormone in Endothelial vasodilation 
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HYPOTHYROIDISM AND DYSLIPIDEMIA: 
Conventionally, subclinical and overt hypothyroidism is associated with 
elevation of total serum and low density lipoprotein (LDL) cholesterol levels 
and normal or elevated high density lipoprotein (HDL) cholesterol levels.27 
Overt and subclinical hypothyroidism is associated with reduced levels of total 
LDL and HDL cholesterols.28 These alterations in lipid metabolism are mainly 
due to the effect of thyroid hormones in regulating the activity of the enzymes 
involved in metabolism of the lipoproteins.  
ACTION OF THYROID HORMONES IN LIPID METABOLISM 
To be more specific, the thyroid hormones regulates the activity of the 
enzyme 3 - hydroxyl – 3 – methyl glutaryl – coenzyme A (HMG – CoA) which 
forms the first step in cholesterol synthesis by catalyzing the conversion of 
HMG - CoA to mevalonate and resulting in elevation of cholesterol levels. 
The thyroid hormones have a key role in activating the LDL receptors, 
the binding of the thyroid hormones to the promoter region of the LDL receptor 
gene which contains a thyroid hormone responsive element (TRE) that allow 
the T3 levels in upregulating the gene expression of LDL receptors.29  
Thyroid hormones also stimulate the enzyme cholesteryl ester transfer 
protein (CETP) that transports cholesteryl esters from HDL2 to the triglycerides 
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and very low density lipoproteins (VLDL) in the opposite direction.30 In 
addition, these hormones also stimulate the enzyme lipoprotein – lipase (LPL) 
that is involved in the metabolism of TGL rich lipoproteins and hepatic lipase 
(HL) an enzyme which converts HDL2 to HDL3.31 
Therefore disturbancess in thyroid function can result in changes in 
composition and transport of lipoproteins.32   With declining thyroid function, 
the levels of total serum and LDL cholesterol are elevated, thereby making 
hypothyroidism an important cause of secondary dyslipidemia.33 
LIPID PROFILE IN OVERT HYPOTHYROIDISM 
Despite lower cholesterol synthesis due to reduced activity of HMG – 
COA reductase enzyme in hypothyroidism, there is an increase in total serum 
cholesterol levels due to raised levels of LDL and intermediate density 
lipoprotein (IDL) cholesterol.  
The main reason for elevated cholesterol levels i.e, the increase in LDL 
and IDL cholesterol concentration in hypothyroidism is mainly due to down 
regulation of LDL receptors leading to decreased receptor mediated 
catabolism of LDL and IDL.34 
Though not very commonly found, there is also decreased activity of 
lipoprotein lipase which metabolises triglyceride rich lipoproteins (VLDL) 
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hence associated with increased TGL and VLDL levels. The VLDL and IDL 
particles in hypothyroid patients are rich in cholesterol and apolipoprotein E 
resembling the lipid profile in type III hyperlipoproteinemia.35 Hence in patients 
who are homozygous for apolipoprotein E 2 allele if super imposed with an 
insult to the thyroid may develop full blown features of type III 
hyperlipoproteinemia.  
Mechanism of increase in HDL Cholesterol levels 
There is an increase in HDL cholesterol levels mainly due to increased 
concentration and also due to decreased catabolism of of HDL2 particles36 
owing to the decreased activity of HL enzyme. There is reduced transfer of 
cholestryl esters from HDL to VLDL due to decreased activity of CETP also 
increasing the HDL cholesterol levels.37  
HYPOTHROIDISM AND ATHEROSCLEROSIS 
There are a number of mechanisms leading to development of 
atherosclerosis in hypothyroidism 
1. T4 has three specific binding sites on apolipoprotein B and inhibits LDL 
oxidation invitro.38 So hypothyroidism favors LDL oxidation39. 
2. Hypothyroidism is associated with increase in serum homocysteine 
levels.40 
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3. Through sympathetic and adrenaline activation41 and increased peripheral 
resistance leading to vessel wall (aortic) stiffness produces diastolic 
hypertension.42 
4. The decrease in thyroid hormones also favors a hypercoagulable state.43 
EVIDENCE SUPPORTING THE ROLE OF HYPOTHYROIDISM IN 
DYSLIPIDEMIA 
The lipid abnormalities seen in hypothyroidism has been found to be 
significantly reduced with L thyroxine (T4) supplementation and also increases 
previously low biliary cholesterol excretion.44 It usually takes around 4 to 6 
weeks of thyroxine supplementation to correct lipid abnormalities in overt 
hypothyroidism. Despite restoring an euthyroid status, the failure of substitution 
therapy to normalise the lipid abnormalities should take into account any 
superimposed dyslipidemia45.  
1. According to a recent meta analysis after initiating substitution therapy 
there is a decrease in serum total and LDL cholesterol levels to 7.9mg/dl 
and 10mg/dl respectively.46 In patients with higher cholesterol levels 
prior to treatment and in hypothyroid patients taking sub optimal T4 doses 
this reduction in cholesterol levels was significantly high.47  
2. Serum lipoprotein a  levels were also found to reduce with thyroxine 
supplementation.48 
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3. Though a less consistent finding serum HDL cholesterol levels were also 
found to decrease with  L – thyroxine (T4) therapy.48 
4. So in total there is a significant decrease in serum total and LDL 
cholesterol, lipoprotein a, apolipoprotein B but such significant changes 
were not seen with HDL cholesterol, triglycerides and apolipoprotein 
AI.49  
In patients with dyslipidemia prevalence of overt hypothyroidism is not 
low.50 
LIPID PROFILE IN SUBCLINICAL HYPOTHRYOIDISM 
Normal levels of T3 and T4 with mildly elevated serum TSH levels up to 
10µIU/ml defines subclinical hypothyroidism (SH). In comparison to overt 
hypothyroidism subclinical hypothyroidism is more common and has a higher 
prevalence in women and elderly.51 It was found that in patients with positive 
anti thyroid anti bodies but with high normal TSH levels (2-4µIU/ml) there was 
increase in total serum cholesterol. 
In comparison with euthyroid controls, patients with subclinical 
hypothyroidism have increased serum total and LDL cholesterol52, 
apolipoprotein B and lipoprotein a – Lp(a). But the levels of HDL cholesterol, 
triglycerides and apolipoprotein AI were not found to be significantly 
increased.53 
55 
 
In patients with antibodies to thyroid peroxidase (TPO) as well as in 
smokers, subclinical hypothyroidism has been associated with increased risk of 
coronary events owing to the lipid abnormalities seen in SH.54 Subclinical 
hypothyroidism impairs endothelial vasodilation by decreasing heart rate 
variability, ventricular function as well as cardio vascular adaptation to effort. In 
women with SH, smoking acts as an additional risk factor in altering the lipid 
profile and aggravating thyroid failure jointly contributing to the development 
of atherosclerosis.55 
ROLE OF THERAPY IN SUBCLINICAL HYPOTHYROIDISM 
There has been conflicting results regarding the effect of L thyroxine 
substitution therapy in reversing the lipid abnormalities in patients with 
subclinical hypothyroidism.56 
Few studies have found that L thyroxine therapy in SH reduced the total 
cholesterol levels by 15mg/dl irrespective of the pretreatment levels.57 In 
contrary few studies have shown a significant decrease in HDL cholesterol by 
6.8%58 and no changes noted in other lipid parameters. Also with patients with 
high cholesterol (TC >240mg/dl) and TSH levels (>10µIU/ml) prior to 
treatment, thyroid substitution therapy brought a considerable lowering of 
serum total and LDL cholesterol levels.59 
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Though many studies support the beneficial role of thyroid replacement 
in reducing dyslipidemia and risk of CAD in overt hypothyroidism, studies 
concerning the treatment of subclinical hypothyroidism is still not conclusive.  
Hence it is evident that thyroid substitution would play a significant 
beneficial role in patients with prominent thyroid dysfunction (TSH>10µIU/ml), 
high pretreatment cholesterol levels and in patients with smoking as an 
additional risk factor.  
However, the beneficial effect of lowering total and LDL cholesterol 
level in SH patients is outweighed by thyroid substitution-induced decrease in 
HDL cholesterol levels. Risk of exacerbating angina or inducing cardiac 
arrhythmia by thyroxine therapy ensures cautious use of supplementation 
therapy when treating people with a previous history of angina. 
In patients with dyslipidemia prevalence of SH is relatively more 
common. Hence ,serum TSH levels should be included in the screening of 
patients with high serum cholesterol levels.60 To conclude, treatment of 
hypercholesterolemic patients with SH results in restoration to a new thyroid 
status along with the reversal of lipid abnormalities, relieves certain symptoms 
and prevents progression of SH to overt hypothyroidism.61 
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AUTOIMMUNE THYROID DISEASE AND LIPOPROTEIN (a) 
In recent studies, increased levels of lipoprotein (a) was found in 
euthyroid males and females with evidence of auto immune thyroid disease 
(increased titers of TPO and/or Thyroglobulin antibodies).62 
However in another study, which compared the levels of lipoprotein (a) in 
euthyroid patients with positive thyroid auto antibodies with age and sex 
matched controls showing no evidence of thyroid auto immunity, the results  
showed no significant difference in lipid profiles including lipoprotein (a) 
between the two groups.63In the above mentioned study, apolipoprotein (a) 
which is known to influence Lp(a), chronic renal failure were also taken into 
account.  
Hence the presence of auto immune thyroid disorders does not have a 
significant role in reversing the lipid abnormalities in patients with subclinical 
hypothyroidism.64 
EVALUATION 
Since hypothyroidism is one of the important causes for secondary 
dyslipidemia, it is of paramount importance to screen for thyroid dysfunction in 
patients presenting with dyslipidemia and also in patients who show an 
unexpected improvement or worsening of the lipid profile. 
 
 
 
 
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
 The study was conducted at Govt. Royapettah Hospital, Chennai between 
April 2014 to September 2014.  
 The study was performed after getting written consent from all the atients 
chosen for the study. Clearance was obtained from ethical committee of Govt. 
Kilpauk College and Hospital, Chennai.  
 
STUDY DESIGN AND PATIENT SELECTION 
        This is a cross sectional, case control study in which 85 patients presenting 
with acute ischemic stroke are taken as cases and 85 people not suffering from 
stroke were selected as controls matched for age, sex and risk factors. 
 
Inclusion Criteria: 
1. patients with acute ischemic stroke  
2. no previous H/O thyroid abnormality 
3. no H/O any chronic drug intake known to interfere with thyroid function. 
 
Exclusion criteria: 
1. Patients with previous H/O thyroid dysfunction. 
2. Cardiac dysfunction leading to embolic stroke. 
3. No e/o TIA, SAH, intraparenchymal hemorrhage or mass lesion on 
radiographic imaging of brain. 
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4. Severe renal function impairment. 
5. Severe liver function impairment. 
6. Patients taking drugs known to interfere with thyroid function. 
METHODOLOGY 
         A total no. of 85 patients presenting with acute ischemic stroke from both 
sexes (51 Males & 34 Females) with age range from 45 to 80 years were 
selected as cases, diagnosis confirmed by CT brain and thyroid profile (free T3, 
T4, TSH) measured in these patients.  
         A total no. of 85 controls (not suffering from stroke) matched for age, sex 
and risk factors were selected from outpatient department, Govt. Royapettah 
Hospital. 
 
          Patients and controls taking drugs that interfered with thyroid function 
were excluded from the study.  
MATERIALS 
Thyroid function was tested by quantitative measurements of free 
triiodothyronine (T3), free Thyroxine (T4) and Thyroid Stimulating hormone 
(TSH) using Chemiluinescent Micro particle Immune Assay (CMIA) technique. 
Under aseptic precautions, using a sterile syringe, 2ml of venous blood was 
withdrawn from a peripheral vein for estimating thyroid profile. 
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Range of Expected Values: 
Free T3 – 1.71-3.70 pg/ml 
Free T4-  0.89- 1.76 ng/dl 
TSH- 0.35- 5.50 µIU/ml 
So patients, with normal T3, T4 levels and elevated TSH levels (< 10 µIU/ml) 
were diagnosed to have subclinical hypothyroidism. Normal TSH levels (0.35-
5.50 µIU/ml). 
 
STATISTICAL ANALYSIS: 
Data was entered in Windows Excel format, data analysis was carried out using 
statistical package of SPSS 15 for determination of statistical significance 
among different variables. Co-relation was assessed using chi-square test. 
A  p value of less than 0.05 was considered as significant.  
 
  
 
 
 
 
 
RESULTS 
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RESULTS AND OBSERVATIONS 
 
DISTRIBUTION OF AGE AMONG CASES 
 
 
  
Observ
ed N Expected N Residual 
P Value 
<= 50 5 21.3 -16.3  
51-60 18 21.3 -3.3 0.000 
61-70 35 21.3 13.8  
71-80 27 21.3 5.8  
Total 85      
 
Table 3: Distribution Of Age Among Cases 
 
 
In the study, 62 were above 60 years and 23 people below 60 years. The 
frequency of ischemic stroke was  more in the age group > 60 years 6(73%) 
compared with age group <60 years.  The p value of  the study which is <0.05 is 
significant. 
 
 The mean age of the patients was (65.86 ± 7.72 SD) years and for control 
(65.64 ± 6.74 SD) years. 
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Figure 16:  Distribution Of Age Among Cases 
 
 
 
 
 
 
 
Figure 17:  Distribution Of Age Among Cases 
 
5 
18 
35 
27 
<= 50 51-60 61-70 71-80
Observed N 
Observed N
35 
27 
0
5
10
15
20
25
30
35
40
>60 years <60 years
age
63 
 
AGE DISTRIBUTION AMONG CASES AND CONTROLS 
 
 
  Diagnosis Total P 
value    Cases Control   
Age 
in 
years 
<= 
50 
Count 
5 1 6 
  
    % within 
Age in 
years 83.30% 16.70% 100.00% 
  
    % within 
Diagnosis 5.90% 1.20% 3.50% 
  
  51-
60 
Count 
18 16 34 
  
    % within 
Age in 
years 52.90% 47.10% 100.00% 
  
    % within 
Diagnosis 21.20% 18.80% 20.00% 
  
  61-
70 
Count 
35 46 81 
  
    % within 
Age in 
years 43.20% 56.80% 100.00% 
  
    % within 
Diagnosis 41.20% 54.10% 47.60% 
  
  71-
80 
Count 
27 22 49 
0.188  
    % within 
Age in 
years 55.10% 44.90% 100.00% 
  
    % within 
Diagnosis 31.80% 25.90% 28.80% 
  
Total Count 85 85 170   
  % within 
Age in 
years 50.00% 50.00% 100.00% 
  
  % within 
Diagnosis 100.00% 100.00% 100.00% 
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Table 4: Distribution Of Age Among Cases and Controls 
The age distribution among cases and controls was equal with a p value of 
0.188 which is not statistically significant. 
 
 
 
Figure 18: Age  Distribution Between Case And Control Groups 
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GENDER DISTRIBUTION BETWEEN CASES AND CONTROLS 
 
 
 
  
Diagnosis Total P Value Cases Control 
 
Male 
Count 51 51 102  
 
 
 
 
1.000 
% within 
Sex 50.00% 50.00% 100.00% 
% within 
Diagnosis 60.00% 60.00% 60.00% 
Female 
Count 34 34 68 
% within 
Sex 50.00% 50.00% 100.00% 
% within 
Diagnosis 40.00% 40.00% 40.00% 
Total 
Count 85 85 170 
% within 
Sex 50.00% 50.00% 100.00% 
% within 
Diagnosis 100.00% 100.00% 100.00% 
 
 
Table 5: Gender Distribution Between Cases And Controls 
 
 
 
In this study, the frequency of ischemic stroke was found to be higher in 
males (51) than females (34) but there was no correlation between gender 
distribution among cases and controls with a p value of 1.000 which showed no 
statistical significance.  
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Figure 19: Gender distribution between case and control groups 
 
 
 
In this study, the frequency of ischemic stroke was found to be higher in 
males (51) than females (34) but there was no correlation between gender 
distribution among cases and controls with a p value of 1.000 which showed no 
statistical significance.  
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RISK FACTOR DISTRIBUTION BETWEEN CASES AND CONTROLS 
 
 
 
  
  
  
  
Diagnosis Total P Value 
Cases Control   
Past 
History 
 
 
 
 
 
 
 
 
 
 
 
Nil Count 34 34 68  
 
 
 
 
 
1.000 
  % within 
Past 
History 
50.0% 50.0% 100.0% 
  % within 
Diagnosis 40.0% 40.0% 40.0% 
DM Count 20 20 40 
  % within 
Past 
History 
50.0% 50.0% 100.0% 
  % within 
Diagnosis 23.5% 23.5% 23.5% 
HT Count 20 20 40 
  % within 
Past 
History 
50.0% 50.0% 100.0% 
  % within 
Diagnosis 23.5% 23.5% 23.5% 
Both Count 11 11 22 
  % within 
Past 
History 
50.0% 50.0% 100.0% 
  % within 
Diagnosis 12.9% 12.9% 12.9% 
Total 
 
 
Count 85 85 170 
% within 
Past 
History 
50.0% 50.0% 100.0% 
% within 
Diagnosis 100.0% 100.0% 100.0% 
 
 
Table 6: Risk Factor Distribution Between Cases And Controls 
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The frequency of risk factors i.e. HT, DM or both was found to be 
equally distributed between cases and controls in the study with a p value of 
1.000 which showed no statistical significance.  
  
 
 
Figure 20: Risk Factor distribution between case and control groups 
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DISTRIBUTION OF SMOKING/ALCOHOLISM AMONG CASES AND 
CONTROLS  
 
  
  
  
  
Diagnosis Total P 
Value Cases Control   
Smoker/ 
Alcoholic 
  
  
  
  
  
Yes 
  
  
Count 29 29 58  
 
 
 
 
1.000 
% within 
Smoker 
/Alcoholic 
50.0% 50.0% 100.0% 
% within 
Diagnosis 34.1% 34.1% 34.1% 
No 
  
  
Count 56 56 112 
% within 
Smoker/ 
Alcoholic 
50.0% 50.0% 100.0% 
% within 
Diagnosis 65.9% 65.9% 65.9% 
Total 
  
  
Count 85 85 170 
% within 
Smoker/ 
Alcoholic 
50.0% 50.0% 100.0% 
% within 
Diagnosis 100.0% 100.0% 100.0% 
 
Table 7: Distribution Of Smoking/Alcoholism Among Cases And Controls 
 
The frequency of smoking / alcoholism was found to be equally 
distributed between cases and controls in the study with a p value of 1.000 
which showed no statistical significance.  
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Figure 19: Distribution Of Smoking/Alcoholism Among Cases And 
Controls 
 
The frequency of smoking / alcoholism was found to be equally 
distributed between cases and controls in the study with a p value of 1.000 
which showed no statistical significance.  
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DISTRIBUTION OF  RT/LT MCA INFARCT AMONG CASES AND 
CONTROLS 
 
 
    Diagnosis Total P 
Value     Cases Control   
CNS Left 
Hemiplegi
a 
Count 
60 0 60 
 
    % within 
CNS 100.0% .0% 100.0% 
0.000 
    % within 
Diagnosis 70.6% .0% 35.3% 
 
  Right 
Hemiplegi
a 
Count 
25 0 25 
 
    % within 
CNS 100.0% .0% 100.0% 
 
    % within 
Diagnosis 29.4% .0% 14.7% 
 
  NFND Count 0 85 85  
    % within 
CNS .0% 100.0% 100.0% 
 
    % within 
Diagnosis .0% 100.0% 50.0% 
 
Total Count 85 85 170  
  % within 
CNS 50.0% 50.0% 100.0% 
 
  % within 
Diagnosis 100.0% 100.0% 100.0% 
 
 
Table 8: Distribution Of  Rt/Lt Mca Infarct Among Cases And Controls 
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Figure 20:  Distribution Of  Rt/Lt Mca Infarct Among Cases And Controls 
 
 
 
The distribution of rt MCA infarct was more common than lt MCA 
infarct among cases with a p value of 0.000 which is significant. 
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COMPARISON OF RENAL AND LIVER FUNCTION TESTS AMONG 
CASES AND CONTROLS 
  
  Diagnosis N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
P 
Value 
Serum Urea Cases 85 30.89 4.816 .522 
>0.05 
  Control 85 31.42 4.910 .533 
Serum 
creatinine 
Cases 85 .787 .0949 .0103 
  Control 85 .791 .0908 .0098 
Serum 
Total 
Protein 
Cases 
85 6.761 .2875 .0312 
  Control 85 6.776 .2918 .0317 
Serum 
Albumin 
Cases 85 4.256 .2233 .0242 
  Control 85 4.269 .2361 .0256 
 
Table 9: Comparison Of Renal And Liver Function Tests Among Cases 
And Controls 
 
 
  
The mean serum urea in cases was 30.89 and in controls was 31.42 with a 
p value of 0.479 which is statistically not significant. 
The mean creatinine in cases was 0.787 and in controls was 0.908 with a 
p value of 0.805 which is statistically not significant. 
 
 
 
 
 
74 
 
  
 
 
Figure 21: Comparison Of Renal Function Tests Among Cases And 
Controls 
 
 
 
The mean total protein value in cases was 6.761 and in controls was 
6.776 with a p value of 0.731 which is statistically not significant. 
 
 
 
 
30.89 
0.787 
31.42 
0.791 
0
5
10
15
20
25
30
35
Serum Urea Serum Creatinine
Cases Controls
75 
 
 
 
 
  
Figure 22:  Comparison of  Liver Function Tests Among Cases and 
Controls 
 
 
 
The mean serum albumin value in cases was 4.256 and in controls was 
4.269 with a p value of 0.714 which is statistically not significant. 
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COMPARISON OF SERUM TRIGLYCERIDE LEVELS AMONG 
CASES AND CONTROLS 
 
  Diagnosis N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
P 
Value 
Serum 
Triglyceride 
(mg/dl) 
Cases 
85 133.92 16.810 1.823 
 
0.761 
  Control 85 134.71 16.896 1.833  
 
  
Table 10: Comparison Of Serum Triglyceride Levels Among Cases And 
Controls 
 
The mean triglyceride level in cases was 133.92 and in controls was 
34.71 and there was no significant difference in serum triglyceride levels 
between cases and controls with a p value of 0.761 that is not statistically 
significant.  
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Figure 23: Serum Triglyceride  distribution between case and control 
groups 
 
The mean triglyceride level in cases was 133.92 and in controls was 
34.71 and there was no significant difference in serum triglyceride levels 
between cases and controls with a p value of 0.761 that is not statistically 
significant.  
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COMPARISON OF BLOOD SUGAR VALUES AMONG CASES AND 
CONTROLS 
 
  
  Diagnosis N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
P Value 
Random 
Blood 
Sugar 
(mgs%) 
Cases 
85 115.98 25.429 2.758 
 
0.953 
  Control 85 116.21 26.015 2.822  
 
 
Table 11: Comparison Of Blood Sugar Values Among Cases And Controls 
 
   
 The mean random blood sugar value in cases was 115.98 and 116.21 in 
controls and with a p value of 0.953 which also shows no statistical 
significance. 
 
 
Figure 24:  Comparison of Blood Sugar Values Among Cases And Controls 
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COMPARISON OF BLOOD PRESSURE MEASUREMENTS AMONG 
CASES AND CONTROLS 
 
  
Diagno
sis N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
P Value 
SBP Cases 85 165.46 10.403 1.128  
  Control 85 131.61 18.505 2.007  
DBP Cases 85 99.98 5.778 .627 .000 
  Control 85 82.94 6.828 .741  
 
 
Table 12 : Comparison Of Blood Pressure Measurements Among Cases 
And Controls 
 
The mean systolic blood pressure in cases was 165.46 and in controls was 
131.61 with a p value of 0.000 which is statistically highly significant. 
The mean diastolic blood pressure in cases was 99.98 and in controls was 
82.94 with a p value of 0.000 which is statistically highly significant. 
 
 
Figure 25: Comparison of Blood Pressure Measurements Among Cases 
And Controls 
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COMPARISON OF DIASTOLIC BLOOD PRESSURE AMONG 
EUTHYROID AND HYPOTHYROID PATIENTS 
 
 TSH N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
P 
VALU
E 
DBP Norm
al 78 99.62 5.730 .649 
 
  Abnor
mal 7 104.00 5.033 1.902 
0.048 
 
 
Table 13 : Comparison of diastolic blood pressure among Euthyroid and 
hypothyroid patients 
 
 In the study, among cases 78 people with normal TSH values had a mean 
DBP of 99.62 and 7 with elevated TSH levels had a mean DBP of 104.00 which 
is significantly higher with a p value of 0.048 which is statistically significant. 
 
 
 
 
Figure 26:  Comparison of diastolic blood pressure among Euthyroid and 
hypothyroid patients 
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COMPARISON OF SERUM TOTAL CHOLESTEROL BETWEEN 
CASES AND CONTROLS 
 
 
    Diagnosis Total P value 
    Cases Control   
Serum 
Total 
Cholestero
l 
Normal Count 
70 81 151 
 
    % within 
Serum 
Total 
Cholestero
l 
46.4% 53.6% 100.0% 
 
    % within 
Diagnosis 82.4% 95.3% 88.8% 
 
  Abnormal Count 15 4 19 0.007 
    % within 
Serum 
Total 
Cholestero
l 
78.9% 21.1% 100.0% 
 
    % within 
Diagnosis 17.6% 4.7% 11.2% 
 
Total Count 85 85 170  
  % within 
Serum 
Total 
Cholestero
l 
50.0% 50.0% 100.0% 
 
  % within 
Diagnosis 100.0% 100.0% 100.0% 
 
 
Table 14 : Comparison Of Serum Total Cholesterol Between Cases And 
Controls 
 
 
 
  
82 
 
In the study, among cases 70 had high serum total cholesterol and 15 had 
elevated serum total cholesterol and among controls 81 had had high serum total 
cholesterol and 4 had elevated serum total cholesterol. The mean serum total 
cholesterol in cases was significantly higher than in  controls but the p value is 
0.007 which is not statistically significant. 
 
 
 
 
Figure 27:  Comparison Of Serum Total Cholesterol Between Cases And 
Controls 
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COMPARISON OF SERUM CHOLESTEROL IN EUTHYROID 
PATIENTS AMONG CASES AND CONTROLS 
 
 
TSH     Diagnosis Total P 
Valu
e     Cases Control   
Normal Serum 
Total 
Cholestero
l 
Normal Count 
69 81 150 
 
      % within 
Serum 
Total 
Cholestero
l 
46.0% 54.0% 100.0% 
 
      % within 
Diagnosis 88.5% 95.3% 92.0% 
 
    Abnormal Count 9 4 13  
      % within 
Serum 
Total 
Cholestero
l 
69.2% 30.8% 100.0% 
0.108 
      % within 
Diagnosis 11.5% 4.7% 8.0% 
 
  Total Count 78 85 163  
  % within 
Serum 
Total 
Cholestero
l 
47.9% 52.1% 100.0% 
 
  % within 
Diagnosis 100.0% 100.0% 100.0% 
 
Abnormal Serum 
Total 
Cholesterol 
Normal Count 
1   1 
 
      % within 
Serum 
Total 
Cholestero
l 
100.0%   100.0% 
 
      % within 
Diagnosis 14.3%   14.3% 
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    Abnorma
l 
Count 6   6  
      % within 
Serum 
Total 
Cholestero
l 
100.0%   100.0% 
<0.00
1 
      % within 
Diagnosis 85.7%   85.7% 
 
  Total Count 7   7  
  % within 
Serum 
Total 
Cholestero
l 
100.0%   100.0% 
 
  % within 
Diagnosis 100.0%   100.0% 
 
 
 
Table 15 : Comparison Of Serum Cholesterol In Euthyroid Patients 
Among Cases And Controls 
 
In the study, among patients with normal TSH levels, 69 of cases and 81 
of controls had normal serum total cholesterol while 9 of cases and 4 of controls 
had elevated serum total cholesterol.  
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Figure 28: Comparison Of Serum Cholesterol In Euthyroid Patients 
Among Cases 
 
The serum total cholesterol among cases and controls with an euthyroid 
pattern was found to have a p value of 0.108 which is not statistically 
significant. 
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DISTRIBUTION OF HYPOTHYROID PATIENTS ACCORDING TO 
SERUM CHOLESTEROL LEVELS  
 
 Elevated TSH 
cases 
Mean  P Value 
Normal Serum 
Cholesterol 
1 14.3  
< 0.001 
Abnormal 
Serum 
Cholesterol 
6 85.7 
 
Table 16 :  Distribution Of Hypothyroid Patients According To Serum 
Cholesterol Levels 
 
In 7 patients with hypothyroidism, 6 patients had elevated serum 
cholesterol with a mean value of 85.7 compared to 1 patient who had normal 
cholesterol value with a mean of 14.3 which is statistically significant with a p 
value of <0.001. 
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Figure 29:   Distribution Of Hypothyroid Patients According To Serum 
Cholesterol Levels 
 
In 7 patients with hypothyroidism, 6 patients had elevated serum 
cholesterol with a mean value of 85.7 compared to 1 patient who had normal 
cholesterol value with a mean of 14.3 which is statistically significant with a p 
value of <0.001. 
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COMPARISON OF FREE TRIIODOTHYRONINE LEVELS AMONG 
CASES AND CONTROLS 
 
    Diagnosis Total P Value     Cases Control   
T3 Normal Count 76 73 149  
    % within 
T3 51.0% 49.0% 100.0% 
 
    % within 
Diagnosis 89.4% 85.9% 87.6% 
0.484 
  Abnormal Count 9 12 21  
    % within 
T3 42.9% 57.1% 100.0% 
 
    % within 
Diagnosis 10.6% 14.1% 12.4% 
 
Total Count 85 85 170  
  % within 
T3 50.0% 50.0% 100.0% 
 
  % within 
Diagnosis 100.0% 100.0% 100.0% 
 
 
Table 17 :  Comparison Of Free Triiodothyronine Levels Among Cases 
And Controls 
 
 
 
In the study, among cases 76 had normal free T3  levels and 9 had low 
free T3  levels. Among controls 73 had normal free T3  levels and 12 had low 
free T3 levels.The free T3levels variation was equal in both cases and controls 
with a p value of 0.484 which is statistically not significant. 
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Figure 30: Comparison Of Free Triiodothyronine Levels Among Cases 
And Controls 
 
In the study, among cases 76 had normal free T3  levels and 9 had low 
free T3  levels. Among controls 73 had normal free T3  levels and 12 had low 
free T3 levels.The free T3levels variation was equal in both cases and controls 
with a p value of 0.484 which is statistically not significant. 
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COMPARISON OF FREE T3LEVELS AMONG CASES AND 
CONTROLS 
  
 
    Diagnosis Total P Value 
    Cases Control   
T4 Normal Count 78 80 158  
    % within 
T4 49.4% 50.6% 100.0% 
0.549 
    % within 
Diagnosis 91.8% 94.1% 92.9% 
 
  Abnormal Count 7 5 12  
    % within 
T4 58.3% 41.7% 100.0% 
 
    % within 
Diagnosis 8.2% 5.9% 7.1% 
 
Total Count 85 85 170  
  % within 
T4 50.0% 50.0% 100.0% 
 
  % within 
Diagnosis 100.0% 100.0% 100.0% 
 
 
Table 18 :  COMPARISON OF FREE T3 LEVELS AMONG CASES AND 
CONTROLS 
 
 
In our study among cases78 had normal freeT4   and 7 had lowT4   levels 
while in controls 80 had normal T4 and 5 had low freeT4   levels. The free T4 
levels variation was equal among cases and controls with a p value of 0.549 
which is statistically not significant. 
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Figure 31: Comparison Of Free T3 levels Among Cases And Controls 
 
In our study among cases78 had normal freeT4   and 7 had lowT4   levels 
while in controls 80 had normal T4 and 5 had low freeT4   levels. The free T4 
levels variation was equal among cases and controls with a p value of 0.549 
which is statistically not significant. 
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DISTRIBUTION OF SICK EUTHYROIDISM AMONG CASES AND 
CONTROLS. 
  
 
    Diagnosis Total P 
Value     Cases Control   
Sick 
Euthyroid 
Normal Count 70 68 138  
    % within 
Sick 
Euthyroid 
50.7% 49.3% 100.0% 
 
    % within 
Diagnosis 82.4% 80.0% 81.2% 
0.695 
  Abnormal Count 15 17 32  
    % within 
Sick 
Euthyroid 
46.9% 53.1% 100.0% 
 
    % within 
Diagnosis 17.6% 20.0% 18.8% 
 
Total Count 85 85 170  
  % within 
Sick 
Euthyroid 
50.0% 50.0% 100.0% 
 
  % within 
Diagnosis 100.0% 100.0% 100.0% 
 
 
Table 19 :  Distribution Of Sick Euthyroidism Among Cases And Controls. 
 
 
In the study, among cases 70 had normal freeT3 and free T4 levels and 15 
had low  freeT3 and free T4 levels.among controls 68 had normal freeT3 and free 
T4 levels  and 17 had low  freeT3 and free T4 levels.  
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Figure 32: Distribution Of Sick Euthyroidism Among Cases And Controls. 
 
 
Sick euthyroid levels was found to be equally distributed between cases 
and controls with a p value of 0.695 which showed no statistical significance. 
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DISTRIBUTION OF TSH LEVELS AMONG CASES AND CONTROLS 
 
  
   Diagnosis Total P Value 
    Cases Control   
TSH Normal Count 78 85 163  
    % within 
TSH 47.9% 52.1% 100.0% 
0.007 
    % within 
Diagnosis 91.8% 100.0% 95.9% 
 
  Abnormal Count 7 0 7  
    % within 
TSH 100.0% .0% 100.0% 
 
    % within 
Diagnosis 8.2% .0% 4.1% 
 
Total Count 85 85 170  
  % within 
TSH 50.0% 50.0% 100.0% 
 
  % within 
Diagnosis 100.0% 100.0% 100.0% 
 
 
 
Table 20 :  Distribution Of Tsh Levels Among Cases And Controls 
 
In our study, out of 85 controls 78 patients had normal TSH levels and 7 
patients had elevated TSH levels compared to controls in which all 85 people 
had normal TSH levels. The p value was <0.05 which is statistically significant. 
 
  
  
95 
 
Risk Estimate 
 
  Value 
95% Confidence 
Interval 
Lower Upper 
For cohort 
Diagnosis = 
Cases 
.479 .408 .562 
N of Valid 
Cases 170     
 
In our study, out of 85 controls 78 patients had normal TSH levels and 7 
patients had elevated TSH levels compared to controls in which all 85 people 
had normal TSH levels. The p value was <0.05 which is statistically significant. 
 
 
 
Figure 33: Distribution Of Tsh Levels Among Cases And Controls 
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DISCUSSION 
The study is a cross sectional case control study done in Govt. 
Royapettah Hospital and 85 patients with acute ischemic stroke are taken as 
cases and 85 people not suffering from stroke  acting as controls matched for 
age, sex and risk factors. Base line  investigations and thyroid hormonal profile 
consisting of free T3, T4 and TSH was measured and the association of 
subclinical hypothyroidism with acute ischemic stroke was studied. 
AGE  
In the study, 62 were above 60 years and 23 people below 60 years. The 
mean age of the patients was (65.86 ± 7.72 SD) years and for control (65.64 ± 
6.74 SD) years. The frequency of ischemic stroke was more in the age group > 
60 years 6(73%) compared with age group <60 years  
These results were consistent with brown et al65 study who showed that 
patient older than 55 years had high risk of stroke ,statistically significance 
(p=0.001). This is because of the fact that the age is one of the most powerful 
independent risk factor for atherosclerosis. 
GENDER    
In our study, majority of patients were males (51) and females (34) with a 
M:F ratio of 2:1 but there was no statistical difference between males and 
females in cases and controls.  
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This is consistent with Rodica E. Petrea66 et al study which  showed no 
statistical difference between male and female especially in age group more 
than 55 years. This can be explained by hormonal changes after menopause that 
makes the risk of ischemic stroke equal in both sexes.  
BLOOD PRESSURE 
The mean systolic blood pressure in cases was higher than in controls 
with a p value of 0.000 and the mean diastolic blood pressure was also higher in 
cases than controls with a p value of 0.000. 
These results were consistent with Johansan et al study67 who showed that 
patient with hypertension high risk of stroke, statistically significance 
(p=0.001). The high blood pressure during an ischemic stroke accounts for the 
auto regulation and neuro protective mechanism of the cerebral vasculature to 
maintain cerebral perfusion.  
DIABETES MELLITUS 
 The mean random blood sugar value in cases was 115.98 and 116.21 in 
controls and with a p value of 0.953 which also shows no statistical 
significance. 
          These results were inconsistent with Elizabeth Bereth Honor et al69 study 
findings support the hypothesis that diabetes may confer excess risk of stroke 
independent of blood pressure. 
 These results were consistent with Ellen Air et al study68, there is no clear 
relationship between hyperglycemia and stroke incidence. 
98 
 
SERUM TRIGLYCERIDE LEVELS 
The mean triglyceride level in cases was 133.92 and in controls was 
134.71 and there was no significant difference in serum triglyceride levels 
between cases and controls with a p value of 0.761 that is not statistically 
significant. 
These results were consistent with Akram Mohammed Al-Mahdawi et al 
study  These results were inconsistent with Funke H70, et al study, in which it 
was noticed, high serum triglyceride levels 50% (95% CI, 29% to 76%) had 
increased risk of fatal or nonfatal stroke.  
SERUM TOTAL CHOLESTEROL 
In our study, among cases 70 had high serum total cholesterol and 15 had 
elevated serum total cholesterol and among controls 81 had had high serum total 
cholesterol and 4 had elevated serum total cholesterol. There was significant 
difference in serum total cholesterol between cases and controls with a 
statistically significant p value of 0.007. 
This was consistent with several other studies  Yamagishi K et al71 which 
showed  excess risk of ischemic stroke was observed in men with serum total 
cholesterol levels of ≥ 6.21 mmol/L than those with the lowest category (<4.65 
mmol/L).   
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SUBCLINICAL HYPOTHYROIDISM 
           In our study, out of 85 controls 78 patients had normal TSH levels and 7 
patients had elevated TSH levels compared to controls in which all 85 people 
had normal TSH levels. patients with subclinical hypothyroidism has high 
association with ischemic stroke which is statistically significant with a p value 
of 0.007.   
This was consistent with Remmel KS et al studies72 which revealed that 
12% of patients with AIS or TIA had hypothyroidism. 
This was consistent with A. Squizzato et al study73 which reveals that 
hypothyroidism as a possible risk factor for atherothrombotic stroke. 
This is explained by the following probable mechanisms.  
1.  Hypothyroidism may lead to decrease myocardial contractility and heart 
rate with increase vascular resistance and hypertension particularly 
diastolic hypertension 
2.  Increase in serum and total and LDL cholesterol levels by down 
regulation of LDL receptors thereby altering endothelial function. 
3.  Reduced endothelium dependent vasodilation and impaired NO 
availability. 
4.  Alteration in the L-arginine-NO pathway leading to impaired NO 
availability. 
5.  Effects of inflammation and autoimmunity also contributes to endothelial 
dysfunction. 
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6.  The direct effect of thyroid hormone, inflammatory status and altered 
lipid profile jointly contributes to impaired endothelium dependent 
vasodilation and progression of atherosclerosis leading to increased 
incidence of stroke. 
HYPOTHYROIDISM AND DIASTOLIC  BLOOD PRESSURE 
In the study, among cases 78 people with normal TSH values had a mean 
DBP of 99.62 and 7 with elevated TSH levels had a mean DBP of 104.00 which 
is significantly higher with a p value of 0.048 which is statistically significant. 
It is consistent with Ikuo Saito et al study74 which states that diastolic blood 
pressure above 160/95 mm Hg (14.8% vs 5.5%; p < 0.01). These results suggest 
a close association between hypertension and hypothyroidism. 
Through sympathetic and adrenaline activation and increased peripheral 
resistance leading to vessel wall (aortic) stiffness produces diastolic 
hypertension. 
HYPOTHYROIDISM AND TOTAL SERUM CHOLESTEROL 
In our study, 7 patients with hypothyroidism, 6 patients had elevated  
serum cholesterol with a mean value of 85.7 compared to 1 patient who had 
normal cholesterol value with a mean of 14.3 which is statistically significant 
with a p value of <0.001. 
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The results were consistent with the E.N Liberopoulos et al study75 found 
an association between SH and aortic atherosclerosis (OR 1.7; 95% CI 1.1 - 
2.6). 
The results were consistent with R. P. F. Dullaart et al study76 which 
showed that Cholesteryl ester transfer activity was 15% lower during 
hypothyroidism (P < 0.02) resulting in high  total cholesterol levels. 
Hypothyroidism causes down regulation of LDL receptors leading to 
decreased receptor mediated catabolism of LDL and IDL and increased serum 
total cholesterol levels. 
OTHER PARAMETERS 
Renal function tests  
The mean serum urea in cases was 30.89 and in controls was 31.42 with a 
p value of 0.479 which is statistically not significant. The mean creatinine in 
cases was 0.787 and in controls was 0.908 with a p value of 0.805 which is 
statistically not significant. 
The results were consistent with Laurent Fauchier et al study77, which 
states that  Renal impairment was not an independent predictor of ischemic 
stroke. 
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Liver function tests  
The mean total protein value in cases was 6.761 and in controls was 
6.776 with a p value of 0.731 which is statistically not significant. 
The mean serum albumin value in cases was 4.256 and in controls was 
4.269 with a p value of 0.714 which is statistically not significant. 
Sick Euthyroid 
In the study, among cases 70 had normal freeT3 and free T4 levels and 15 
had low  freeT3 and free T4 levels.among controls 68 had normal freeT3 and free 
T4 levels  and 17 had low  freeT3 and free T4 levels. 
The results were consistent with Hershman J M et al study78 which 
showed that Low concentrations of T3 or T4, ro both, in nonthyroidal illnesses 
may have a homeostatic signficance. Low serum concentrations of T4 correlate 
with poor prognosis in nonthyroidal illnesses. 
 
 
 
 
 
 
 
 
  
 
 
 
 
CONCLUSION 
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CONCLUSIONS: 
 
1. Subclinical hypothyroidism per se caused reduced endothelium 
dependent vasodilation and impaired NO availability.  
2. Altered lipid profile was found to have a significant association with sub 
clinical hypothyroidism, especially total serum cholesterol and LDL 
cholesterol. 
3. Chronic inflammation associated with auto immune thyroid disorders 
may play a role in causing endothelial dysfunction. 
4. Subclinical hypothyroidism was found to be an independent, modifiable 
risk factor for stroke 
5. Hence suggested emphasis on thyroid profile measurements, early 
diagnosis and management and its potential role as a modifiable risk 
factor in stroke prevention.  
 
 
 
 
 
 
 
  
  
 
 
 
 
LIMITATIONS 
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LIMITATIONS OF THE STUDY: 
1. The sample size was relatively small. Since the prevalence of subclinical 
hypothyroidism is low in the general population, a large sample size 
would yield a better understanding of co relation between the studied 
variables. 
2. A systematic investigation of stroke risk, comparing hThy to non-hThy 
subjects, contolling for other known risk factors is needed to further 
elucidate this relationship. 
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DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS 
Stroke is one of the leading causes of morbidity and mortality and is also 
one of the major non communicable diseases having a significant impact on the 
socio economic and health status of the general population. Apart from the 
conventional risk factors, identification and treatment of modifiable risk factors 
can significantly reduce the incidence of stroke. 
Subclinical hypothyroidism was found to be associated with altered lipid 
profile, endothelial dysfunction, increased peripheral resistance in vessel walls 
resulting in diastolic hypertension all favouring towards progression of 
atherosclerosis, the forerunner of stroke. 
In the study conducted in our hospital, there was a significant association 
of subclinical hypothyroidism and acute ischemic stroke with a p value of 0.007 
which was statistically significant. 
 Therefore, subclinical hypothyroidism may have a role in stroke 
prevention in the presence/absence of other risk factors. In addition to this early 
diagnosis and management plays a significant role in reducing dyslipidemia and 
its attending  macrovascular complications. 
So, owing to its low cost and easy availability, this could serve as a useful 
tool in identifying and preventing patients at risk for stroke thereby reducing  
the amount of health burden in the community. 
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ANNEXURES 
ABBREVIATIONS 
 
Apo a   –  apolipoprotein a 
Lp a   – lipoprotein a  
LDL   – low density lipoprotein 
HDL    – high density lipoprotein 
TGL   – triglycerides 
NO   – nitric oxide 
T3   – triiodothyronine 
T4   – Thyroxine 
TSH   – thyroid stimulating hormone 
SH   – subclinical hypothyroidism  
SBP   – systolic blood pressure 
DBP   – diastolic blood pressure 
Tg   – thyroglobulin 
TPO   – Thyroperoxidase 
NIS   – Sodium iodide symporter 
TRH   – thyrotropin releasing hormone 
CT   – Computerised tomography 
ROS   – Reactive oxygen species 
eNOS   -- Endothelial nitric oxide synthetase 
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